1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Data availability
The RNA-Seq data generated in this study were deposited in the Gene Expression
Omnibus (GEO) database under the accession code GSE222984. Supplementary
Data 1–4 comprise the list of DEGs derived from RNA-seq data corresponding to the
29.
Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M. & Jemal, A. Global cancer in
women: burden and trends. Cancer Epidemiol. Biomarkers Prev. 26, 444–457 (2017).
Yee, D. et al. Association of event-free and distant recurrence-free survival
with individual-level pathologic complete response in neoadjuvant treatment
of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2
adaptively randomized clinical trial. JAMA Oncol. 6, 1355–1362 (2020).
Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer
drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013).
Collado, M., Blasco, M. A. & Serrano, M. Cellular senescence in cancer and
aging. Cell 130, 223–233 (2007).
Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179,
813–827 (2019).
Dodig, S., Čepelak, I. & Pavić, I. Hallmarks of senescence and aging. Biochem.
Med. 29, 030501 (2019).
Regulski, M. J. Cellular senescence: what, why, and how. Wounds 29, 168–174
(2017).
Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of
senescence. Genes Dev. 24, 2463–2479 (2010).
Prieur, A. & Peeper, D. S. Cellular senescence in vivo: a barrier to
tumorigenesis. Curr. Opin. Cell Biol. 20, 150–155 (2008).
Pérez-Mancera, P. A., Young, A. R. & Narita, M. Inside and out: the activities
of senescence in cancer. Nat. Rev. Cancer 14, 547–558 (2014).
Muñoz-Espín, D. & Serrano, M. Cellular senescence: from physiology to
pathology. Nat. Rev. Mol. Cell Biol. 15, 482–496 (2014).
Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits
liver cancer development. Nature 479, 547–551 (2011).
Wei, W. & Ji, S. Cellular senescence: molecular mechanisms and
pathogenicity. J. Cell. Physiol. 233, 9121–9135 (2018).
Ruscetti, M. et al. Senescence-induced vascular remodeling creates therapeutic
vulnerabilities in pancreas cancer. Cell 181, 424.e1–441.e1 (2020).
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J. & Kirkland, J. L. Cellular
senescence and the senescent secretory phenotype: therapeutic opportunities.
J. Clin. Investig. 123, 966–972 (2013).
Lecot, P., Alimirah, F., Desprez, P. Y., Campisi, J. & Wiley, C. Contextdependent effects of cellular senescence in cancer development. Br. J. Cancer
114, 1180–1184 (2016).
Demaria, M. et al. Cellular senescence promotes adverse effects of
chemotherapy and cancer relapse. Cancer Discov. 7, 165–176 (2017).
Supek, F. et al. A novel accessory subunit for vacuolar H(+)-ATPase from
chromaffin granules. J. Biol. Chem. 269, 24102–24106 (1994).
Ludwig, J. et al. Identification and characterization of a novel 9.2-kDa
membrane sector-associated protein of vacuolar proton-ATPase from
chromaffin granules. J. Biol. Chem. 273, 10939–10947 (1998).
Kinouchi, K. et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H
+-ATPase assembly in murine cardiomyocytes. Circ. Res. 107, 30–34 (2010).
Oshima, Y. et al. Prorenin receptor is essential for normal podocyte structure
and function. J. Am. Soc. Nephrol. 22, 2203 (2011).
Forgac, M. Structure and properties of the vacuolar (H+)-ATPases. J. Biol.
Chem. 274, 12951–12954 (1999).
Futai, M., Sun-Wada, G. H., Wada, Y., Matsumoto, N. & Nakanishi-Matsui,
M. Vacuolar-type ATPase: a proton pump to lysosomal trafficking. Proc. Jpn.
Acad. Ser. B Phys. Biol. Sci. 95, 261–277 (2019).
Forgac, M. Vacuolar ATPases: rotary proton pumps in physiology and
pathophysiology. Nat. Rev. Mol. Cell Biol. 8, 917–929 (2007).
Ochotny, N., Voronov, I., Owen, C., Aubin, J. E. & Manolson, M. F. The
R740S mutation in the V-ATPase a3 subunit results in osteoclast apoptosis
and defective early-stage autophagy. J. Cell. Biochem. 114, 2823–2833 (2013).
Rujano, M. A. et al. Mutations in the X-linked ATP6AP2 cause a glycosylation
disorder with autophagic defects. J. Exp. Med. 214, 3707–3729 (2017).
Abbas, Y. M., Wu, D., Bueler, S. A., Robinson, C. V. & Rubinstein, J. L.
Structure of V-ATPase from the mammalian brain. Science 367, 1240–1246
(2020).
Cruciat, C. M. et al. Requirement of prorenin receptor and vacuolar H
+-ATPase-mediated acidification for Wnt signaling. Science 327, 459–463
(2010).
Logan, C. Y. & Nusse, R. The Wnt signaling pathway in development and
disease. Annu. Rev. Cell Dev. Biol. 20, 781–810 (2004).
COMMUNICATIONS BIOLOGY | (2023)6:1147 | https://doi.org/10.1038/s42003-023-05433-6 | www.nature.com/commsbio
15
ARTICLE
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-023-05433-6
30. Polakis, P. Wnt signaling and cancer. Genes Dev. 14, 1837–1851 (2000).
31. Beitia, M. et al. (Pro)renin receptor expression increases throughout the
colorectal adenoma-adenocarcinoma sequence and it is associated with worse
colorectal cancer prognosis. Cancers 11, 6 (2019).
32. Wang, J., Nishiyama, A., Matsuyama, M., Wang, Z. & Yuan, Y. The (pro)renin
receptor: a novel biomarker and potential therapeutic target for various
cancers. Cell Commun. Signal. 18, 39 (2020).
33. Ohba, K. et al. Expression of (pro)renin receptor in breast cancers and its
effect on cancercell proliferation. Biomed. Res. 35, 117–126 (2014).
34. Wendling, O. et al. Atp6ap2 ablation in adult mice impairs viability through
multiple organ deficiencies. Sci. Rep. 7, 9618 (2017).
35. Binger, K. J. et al. Atp6ap2 deletion causes extensive vacuolation that
consumes the insulin content of pancreatic β cells. Proc. Natl Acad. Sci. USA
116, 19983–19988 (2019).
36. Li, W. et al. Neuron-specific (pro)renin receptor knockout prevents the
development of salt-sensitive hypertension. Hypertension 63, 316–323 (2014).
37. Geisberger, S. et al. New role for the (pro)renin receptor in T-cell
development. Blood 126, 504–507 (2015).
38. Bogdanov, A. et al. Tumor acidity: from hallmark of cancer to target of
treatment. Front. Oncol. 12, 979154 (2022).
39. Czowski, B. J., Romero-Moreno, R., Trull, K. J. & White, K. A. Cancer and pH
dynamics: transcriptional regulation, proteostasis, and the need for new
molecular tools. Cancers 12, 10 (2020).
40. Webb, B. A., Chimenti, M., Jacobson, M. P. & Barber, D. L. Dysregulated pH:
a perfect storm for cancer progression. Nat. Rev. Cancer 11, 671–677 (2011).
41. White, K. A., Grillo-Hill, B. K. & Barber, D. L. Cancer cell behaviors mediated
by dysregulated pH dynamics at a glance. J. Cell Sci. 130, 663–669 (2017).
42. Nishie, M. et al. Downregulated ATP6V1B1 expression acidifies the intracellular
environment of cancer cells leading to resistance to antibody-dependent cellular
cytotoxicity. Cancer Immunol. Immunother. 70, 817–830 (2021).
43. Bergmann, M., Schütt, F., Holz, F. G. & Kopitz, J. Inhibition of the ATPdriven proton pump in RPE lysosomes by the major lipofuscin fluorophore
A2-E may contribute to the pathogenesis of age-related macular degeneration.
FASEB J. 18, 562–564 (2004).
44. Hu, Y.-B., Dammer, E. B., Ren, R.-J. & Wang, G. The endosomal-lysosomal
system: from acidification and cargo sorting to neurodegeneration. Transl.
Neurodegener. 4, 18 (2015).
45. Eskelinen, E. L. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and
autophagy. Mol. Aspects Med. 27, 495–502 (2006).
46. Saftig, P. & Klumperman, J. Lysosome biogenesis and lysosomal membrane
proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 10, 623–635
(2009).
47. Coppé, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescenceassociated secretory phenotype: the dark side of tumor suppression. Annu.
Rev. Pathol. 5, 99–118 (2010).
48. He, S. & Sharpless, N. E. Senescence in health and disease. Cell 169,
1000–1011 (2017).
49. Johmura, Y. et al. Senolysis by glutaminolysis inhibition ameliorates various
age-associated disorders. Science 371, 265–270 (2021).
50. Kim, Y. Y. et al. Cooperation between p21 and Akt is required for p53dependent cellular senescence. Aging Cell 16, 1094–1103 (2017).
51. Herranz, N. & Gil, J. Mechanisms and functions of cellular senescence. J. Clin.
Investig. 128, 1238–1246 (2018).
52. Chen, L. et al. 1,25-Dihydroxyvitamin D exerts an antiaging role by activation
of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence
signaling. Aging Cell 18, e12951 (2019).
53. Wagner, K. D. & Wagner, N. The senescence markers p16INK4A, p14ARF/
p19ARF, and p21 in organ development and homeostasis. Cells 11, 12 (2022).
54. Bojko, A. et al. Improved autophagic flux in escapers from doxorubicininduced senescence/polyploidy of breast cancer cells. Int. J. Mol. Sci. 21, 6084
(2020).
55. Eom, Y.-W. et al. Two distinct modes of cell death induced by doxorubicin:
apoptosis and cell death through mitotic catastrophe accompanied by
senescence-like phenotype. Oncogene 24, 4765–4777 (2005).
56. Jackson, J. G. & Pereira-Smith, O. M. Primary and compensatory roles for RB
family members at cell cycle gene promoters that are deacetylated and
downregulated in doxorubicin-induced senescence of breast cancer cells. Mol.
Cell. Biol. 26, 2501–2510 (2006).
57. Piegari, E. et al. Doxorubicin induces senescence and impairs function of
human cardiac progenitor cells. Basic Res. Cardiol. 108, 334 (2013).
58. Rebbaa, A., Zheng, X., Chou, P. M. & Mirkin, B. L. Caspase inhibition switches
doxorubicin-induced apoptosis to senescence. Oncogene 22, 2805–2811 (2003).
59. Sun, T. et al. Characterization of cellular senescence in doxorubicin-induced
aging mice. Exp. Gerontol. 163, 111800 (2022).
60. Chong, Q.-Y. et al. A unique CDK4/6 inhibitor: current and future therapeutic
strategies of abemaciclib. Pharmacol. Res. 156, 104686 (2020).
16
61. Ozman, Z., Guney Eskiler, G. & Sekeroglu, M. R. In vitro therapeutic effects of
abemaciclib on triple-negative breast cancer cells. J. Biochem. Mol. Toxicol. 35,
e22858 (2021).
62. Zhang, J., Xu, D., Zhou, Y., Zhu, Z. & Yang, X. Mechanisms and implications
of CDK4/6 inhibitors for the treatment of NSCLC. Front. Oncol. 11, 676041
(2021).
63. Wang, D. et al. Loss of legumain induces premature senescence and mediates
aging-related renal fibrosis. Aging Cell 21, e13574 (2022).
64. Li, D. L. et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting
lysosome acidification. Circulation 133, 1668–1687 (2016).
65. Jung, Y.-S. et al. TMEM9 promotes intestinal tumorigenesis through vacuolarATPase-activated Wnt/β-catenin signalling. Nat. Cell Biol. 20, 1421–1433 (2018).
66. Colacurcio, D. J. & Nixon, R. A. Disorders of lysosomal acidification-The
emerging role of v-ATPase in aging and neurodegenerative disease. Ageing
Res. Rev. 32, 75–88 (2016).
67. Song, Q., Meng, B., Xu, H. & Mao, Z. The emerging roles of vacuolar-type
ATPase-dependent lysosomal acidification in neurodegenerative diseases.
Transl. Neurodegener. 9, 17 (2020).
68. Kawai, A., Uchiyama, H., Takano, S., Nakamura, N. & Ohkuma, S.
Autophagosome-lysosome fusion depends on the pH in acidic compartments
in CHO cells. Autophagy 3, 154–157 (2007).
69. Klionsky, D. J., Elazar, Z., Seglen, P. O. & Rubinsztein, D. C. Does bafilomycin
A1 block the fusion of autophagosomes with lysosomes? Autophagy 4,
849–850 (2008).
70. Georgilis, A. et al. PTBP1-mediated alternative splicing regulates the
inflammatory secretome and the pro-tumorigenic effects of senescent cells.
Cancer Cell 34, 85.e9–102.e9 (2018).
71. Guccini, I. et al. Senescence reprogramming by TIMP1 deficiency promotes
prostate cancer metastasis. Cancer Cell 39, 68.e9–82.e9 (2021).
72. Ansieau, S. et al. Induction of EMT by twist proteins as a collateral effect of
tumor-promoting inactivation of premature senescence. Cancer Cell 14, 79–89
(2008).
73. Janda, E. et al. Ras and TGF[beta] cooperatively regulate epithelial cell
plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol. 156,
299–313 (2002).
74. Smit, M. A. & Peeper, D. S. Epithelial-mesenchymal transition and senescence:
two cancer-related processes are crossing paths. Aging 2, 735–741 (2010).
75. Faheem, M. M. et al. Convergence of therapy-induced senescence (TIS) and
EMT in multistep carcinogenesis: current opinions and emerging perspectives.
Cell Death Discov. 6, 51 (2020).
76. Wang, T. W. et al. Blocking PD-L1-PD-1 improves senescence surveillance
and ageing phenotypes. Nature 611, 358–364 (2022).
77. Onorati, A. et al. Upregulation of PD-L1 in senescence and aging. Mol. Cell.
Biol. 42, e0017122 (2022).
78. Bartek, J., Hodny, Z. & Lukas, J. Cytokine loops driving senescence. Nat. Cell
Biol. 10, 887–889 (2008).
79. Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a
leading role for STAT3. Nat. Rev. Cancer 9, 798–809 (2009).
80. Grivennikov, S. I. & Karin, M. Dangerous liaisons: STAT3 and NF-kappaB
collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21, 11–19
(2010).
81. Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low
memory requirements. Nat. Methods 12, 357–360 (2015).
82. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose
program for assigning sequence reads to genomic features. Bioinformatics 30,
923–930 (2014).
83. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc
4, 44–57 (2009).
84. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl Acad.
Sci. USA 102, 15545–15550 (2005).
85. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark
gene set collection. Cell Syst. 1, 417–425 (2015).
Acknowledgements
We thank the Medical Research Support Center (MRSC), Graduate School of Medicine,
Kyoto University for providing the research instruments. We thank KEYENCE for
providing the fluorescence microscope used in this study. We also thank Masahiro
Kawashima, Fengling Pu, Yukiko Fukui, and Yuki Nakamura for their helpful suggestions. This study was supported in part by the Japan Science and Technology Agency
Support for Pioneering Research Initiated by the Next Generation (JST-SPRING; grant
number JPMJSP2110). This work was also supported by a scholarship from the China
Scholarship Council under Grant No.202208050044.
COMMUNICATIONS BIOLOGY | (2023)6:1147 | https://doi.org/10.1038/s42003-023-05433-6 | www.nature.com/commsbio
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-023-05433-6
ARTICLE
Author contributions
Correspondence and requests for materials should be addressed to Kosuke Kawaguchi.
W.L., K.K., M.T., and E.S. contributed substantially to project design. W.L. performed the
experiments and analyzed the data. W.L., C.H., and Y.M. analyzed the RNA-Seq data and
interpreted the results. K.K. and S.T. provided suggestions and technical support for the
experiments. W.L. drafted the manuscript. K.K. and M.T. supervised the study and
revised the manuscript. All authors have approved the submitted version of the manuscript and agreed to be accountable for any part of this work.
Peer review information Communications Biology thanks Mara De Martino and the
other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Primary handling editors: Georgios Giamas and Manuel Breuer. A peer review file is
available.
Reprints and permission information is available at http://www.nature.com/reprints
Competing interests
The authors declare the following competing interests: K.K.: grants from TERUMO,
Astellas, Eli Lilly, and Kyoto Breast Cancer Research Network; consulting fees from
Becton Dickinson, Japan; honoraria from Eisai, Chugai, and Takeda. M.T.: grants from
Chugai, Takeda, Pfizer, Kyowa-Kirin, Taiho, JBCRG Associates, Eisai, Eli Lilly, DaiichiSankyo, AstraZeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI Technology,
Luxonus, Shionogi, and GL Science; honoraria from Chugai, Takeda, Pfizer, KyowaKirin, Taiho, Eisai, Daiichi-Sankyo, AstraZeneca, Eli Lilly, MSD, Exact Science, Novartis,
Konica Minolta, Shimadzu, Yakult, and Nippon Kayaku; advisory board of Kyowa-Kirin,
Daiichi-Sankyo, Eli Lilly, Konica Minolta, BMS, Athenex Oncology, Bertis, Terumo,
Kansai Medical Net; board of directors of JBCRG Associates, KBCRN, OOTR; Associate
Editor of the British Journal of Cancer, Scientific Reports, Breast Cancer Research and
Treatment, Cancer Science, Frontiers in Women’s Cancer, Asian Journal of Surgery, Asian
Journal of Breast Surgery; deputy editor of International Journal of Oncology. The other
authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s42003-023-05433-6.
© The Author(s) 2023
COMMUNICATIONS BIOLOGY | (2023)6:1147 | https://doi.org/10.1038/s42003-023-05433-6 | www.nature.com/commsbio
17
...
論文の公開元へ
